Provider: BuySellSignals Research
Provider: Thomson Reuters Stock Report
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Ranbaxy Laboratories Ltd Receives Approval From CDSCO To Market Synriam
Ranbaxy Laboratories Ltd announced that it has received Central Drugs Standard Control Organisation (CDSCO) approval to market Synriam (arterolane maleate and piperaquine phosphate tablet 150+750 mg) in India for the treatment of uncomplicated malaria in adults caused by plasmodium vivax parasite. Phase III clinical trials for the drug conducted in India, successfully demostrated the efficacy and tolerability for Synriam as comparable to chloroquine. The Company also received permission to conduct Phase III clinical trials for the pediatric formulation in the pediatric patients of uncomplicated plasmodium falciparum malaria.
Latest Developments for Ranbaxy Laboratories Ltd
- Ranbaxy Laboratories receives FDA approval for Valsartan
- Sun Pharmaceutical Industries Ltd to acquire Ranbaxy Laboratories Ltd in $4 billion transaction
- EU, UK evaluating FDA findings on Ranbaxy Laboratories Ltd's Toansa facility-businesstoday
- Ranbaxy Laboratories Ltd Announces Change Of Financial Year
Latest Key Developments in Pharmaceuticals
- Share this
- Digg this